HPV DNA detection and genotyping in 21 cases of primary invasive squamous cell carcinoma of the vagina

Ferreira, Marcel T.; Martins, Luciana; Félix, Ana

doi:10.1038/modpathol.2008.91

Cited by 32 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human papillomavirus positivity was detected in 43% of the patients with PCV in our study, which is slightly lower compared with previously reported data from meta-analyses (Smith et al , 2009) and other studies (Ferreira et al , 2008; Insinga et al , 2008; De Vuyst et al , 2009; Fuste et al , 2010; Brunner et al , 2011; Alonso et al , 2012; Larsson et al , 2013), with a prevalence ranging between 51.4% and 81%. This variation is most likely due to differences in the detection methods used and in the selection of patients, but the geographical variation in HPV prevalence is another possibility.…”

Section: Discussioncontrasting

confidence: 86%

Human papillomavirus, p16INK4A, and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina

et al. 2014

View full text Add to dashboard Cite

Background:This study aimed to determine human papillomavirus (HPV) status and to investigate p16INK4A and Ki-67 expression and their correlation with clinical parameters and survival in women with primary carcinoma of the vagina (PCV).Methods:The presence of HPV DNA was evaluated by PCR. Genotyping was performed by Luminex in 68 short-term (⩽2 years) and long-term (⩾8 years) PCV survivors. p16INK4A and Ki-67 expression was evaluated by immunohistochemistry.Results:Human papillomavirus DNA was detected in 43% of patients, the majority (63%) of whom were HPV16 positive. High p16INK4A expression was significantly correlated with low histopathological grade (P=0.004), HPV positivity (P=0.032), and long-term survival (P=0.045). High Ki-67 expression was negatively correlated with histopathological grade (P<0.001) and tumour size (P=0.047). There was an association between HPV positivity and low histopathological grade, but not between HPV positivity and survival.Conclusion:High p16INK4A expression was associated with long-term survival, but the only independent predictors for survival were tumour size and histopathological grade. Our results indicate that p16INK4A and Ki-67 expression might be useful in tumour grading, and that it might be possible to use p16INK4A expression as a marker for HPV positivity, but this has to be further elucidated.

show abstract

Section: Discussioncontrasting

confidence: 86%

Human papillomavirus, p16INK4A, and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In this multicenter study which spanned 11 years , of the 60 samples examined, 75% were HPV positive, much higher than most previously published results 8,10,14-16 . Ostrow et al 8 found HPV in 21% of 14 patients by using in situ hybridization.…”

Section: Discussioncontrasting

confidence: 53%

“…Using southern blot hybridization, Ikenberg et al , found 55% of 18 patients positive for HPV 10 . Koyamatsu and colleagues 15 and Ferreira et al 16 both used polymerase chain reaction for detection and found HPV in 53% and 81% of 40 and 21 patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer From a Registry-Based Population

Sinno

Saraiya

Thompson

et al. 2014

Obstetrics & Gynecology

View full text Add to dashboard Cite

Objective To describe the human papillomavirus (HPV) genotype distribution in invasive vaginal cancers diagnosed prior to the introduction of the HPV vaccine, and evaluate if survival differed by HPV status. Methods Four population-based registries and three residual tissue repositories provided formalin-fixed, paraffin-embedded tissue from microscopically confirmed primary vaginal cancer cases diagnosed between 1994 and 2005 that were tested by L1 consensus polymerase chain reaction with type-specific hybridization in a central laboratory. Clinical, demographic, and all-cause survival data were assessed by HPV status. Results Sixty cases of invasive vaginal cancer were included. HPV was detected in 75% (45) and 25% (15) were HPV negative. HPV 16 was most frequently detected (55%, 33/60) followed by HPV 33 (18.3%, 11/60). Only one case was positive for HPV 18 (1.7%) Multiple types were detected in 15% of the cases. Vaginal cancers in women < 60 were more likely to be HPV 16 or HPV 18 positive (HPV 16/18) than older women; 77.3% vs. 44.7% (P = .038). The median age at diagnosis was younger in the HPV16/18 (59 years) group vs. other HPV positive (68 years) and no HPV (77 years) (P =.003). The HPV distribution did not significantly vary by race or ethnicity or place of residence. The 5-year unadjusted all-cause survival was 57.4% for women with HPV-positive vaginal cancers vs. 35.7% among those with HPV-negative tumors (p=0.243). Conclusion Three quarters of all vaginal cancers in the United States had HPV detected, much higher than previously found , and 57% could be prevented by current HPV vaccines, .

show abstract

“…1,[4][5][6][7] Previous studies regarding HPV types in VAIN and vaginal cancer or comparisons of HPV types between incident vaginal and previous cervical lesions were limited by small sample sizes and inconsistent conclusions. 3,4,[8][9][10][11][12][13][14][15] Smith et al 8 published a systemic review of 725 abstracts, in which the HPV detection rates among 166 cases of VAIN2/3 and 66 cases of VAIN1 were 92.6% and 98.5%, respectively. Another systemic review of 22 U.S. studies found HPV16/18 to be the predominant type in VAIN3 (n ¼ 97, 65.1%).…”

mentioning

confidence: 99%

Human papillomavirus in vaginal intraepithelial neoplasia

Chao

Chen

Hsueh

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

There are limited data on the prevalence and distribution of human papillomavirus (HPV) genotypes in vaginal intraepithelial neoplasia (VAIN). We sought to clarify this issue in a series of 450 VAIN cases with a confirmed diagnosis between 1990 and 2006. HPV genotyping was performed using paraffin-embedded specimens and polymerase chain reaction (PCR)-based methods. Multiple HPV types were validated by E6 type-specific PCR and direct sequencing. The HPV genotypes of the vaginal and cervical neoplasms were compared for those with incident VAIN and a history of previous/concomitant cervical neoplasms. Ki-67 was performed for supporting diagnosis of VAIN. Of these 450 VAIN cases (median age, 59 years; range, 19-93), two with missing paraffin blocks and 54 with poor DNA quality were excluded. HPV was detected in 273/394 (69.3%) VAIN, and multiple infections were found in 17.9% of HPV-positive samples. The leading types were HPV16 (35.5%), HPV58 (9.9%), HPV52 (9.9%), HPV39 (8.4%), HPV33 (7.3%) and HPV53 (7.0%). Among the 156 cases with a history of previous cervical neoplasia, 29.0% had concordant HPV genotypes, while synchronous VAIN samples (n 5 49) were more likely to harbor concordant genotypes (58.7%) with the concomitant cervical neoplasm (p 5 0.0003). Whether those HPV types in the incident VAIN lesions had existed in the vaginal epithelium at the time of the previous cervical neoplasia or a new acquisition needs to be clarified in prospective follow-up studies.The natural history of invasive vaginal cancer and preinvasive lesions (vaginal intraepithelial neoplasia [VAIN]) has been minimally investigated compared to invasive cervical cancer and cervical intraepithelial neoplasia (CIN). 1,2 Many previous research efforts have indicated that invasive vaginal cancer and VAIN share common risk factors with cervical neoplasms, including the number of lifetime sexual partners, smoking and infection with human papillomavirus (HPV). 1,3,4 Previous radiation exposure, a previous history of cervical neoplasms, diethylstilbestrol exposure and an immune-compromised state were also associated with an increased risk of vaginal cancer and VAIN. 1,[4][5][6][7] Previous studies regarding HPV types in VAIN and vaginal cancer or comparisons of HPV types between incident vaginal and previous cervical lesions were limited by small sample sizes and inconsistent conclusions. 3,4,[8][9][10][11][12][13][14][15] Smith et al. 8 published a systemic review of 725 abstracts, in which the HPV detection rates among 166 cases of VAIN2/3 and 66 cases of VAIN1 were 92.6% and 98.5%, respectively. Another systemic review of 22 U.S. studies found HPV16/18 to be the predominant type in VAIN3 (n ¼ 97, 65.1%). 10 A meta-analysis of 93 studies 9 including 298 cases of VAIN from four continents noted that HPV testing was positive in 100% of VAIN1 and 90.1% of VAIN2/3. In VAIN2/3 (n ¼ 191), the most common HPV types were HPV16 (57.6%), HPV 18 (6.9%) and HPV 58 (5.9%). 9 With the advent of HPV vaccines, cervical neoplasms of the HPV types included in th...

show abstract

HPV DNA detection and genotyping in 21 cases of primary invasive squamous cell carcinoma of the vagina

Cited by 32 publications

References 28 publications

Human papillomavirus, p16INK4A, and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina

Human papillomavirus, p16INK4A, and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina

Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer From a Registry-Based Population

Human papillomavirus in vaginal intraepithelial neoplasia

Contact Info

Product

Resources

About